CLAIMS

1. A fused pyrimidine derivative or a pharmaceutically acceptable salt thereof represented by Formula (I):



(I)

{wherein R^1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; n represents an integer of 0 to 3; X^1 and X^2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; and formula (II):

(II)

represents formula (III):



(III)

[wherein X--Y--Z represents $R^2C=CR^3-NR^4$ (wherein R^2, R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group), $R^2C=N-NR^4$ (wherein R^2 and R^4 have the same meanings as defined above, respectively), $R^4N-CR^3=CR^2$ (wherein R^2, R^3 and R^4 have the same meanings as defined above, respectively), or $R^4N-N=CR^2$ (wherein R^2 and R^4 have the same meanings as defined above, respectively)] or formula (IV):



(IV)

[wherein Xa--Ya--Za represents $R^2HC-NR^3-CHR^4$ (wherein R^2, R^3 and R^4 have the same meanings as defined above, respectively), R^2HC-NR^3-NH (wherein R^2 and R^3 have the same meanings as defined above, respectively), or $NH-NR^3-CHR^4$ (wherein R^3 and R^4 have the same meanings as defined above, respectively)]}.

2. The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is substituted or unsubstituted lower alkyl.

3. The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R^3 is substituted or unsubstituted aryl, or substituted or

unsubstituted lower alkyl.

4. The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein X^1 is substituted or unsubstituted aralkyl and X^2 is a hydrogen atom.

5. A Pharmaceutical composition comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

6. A therapeutic agent for diabetes comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

7. A preventive and/or therapeutic agent for diabetic complications comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

8. A blood glucose-lowering agent comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

9. An insulin secretagogue comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

10. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of a therapeutic agent for diabetes.

11. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of a preventive and/or therapeutic agent for diabetic complications.

12. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of a blood glucose-lowering agent.

13. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of an insulin secretagogue.

14. A method for treating diabetes, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

15. A method for preventing and/or treating diabetic complications, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

16. A method for lowering blood glucose levels, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

17. A method for stimulating secretion of insulin, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.